Axsome Therapeutics, Inc. (AXSM): Free Cash Flow
-$93.89M
Year ended 2025-12-31
-$71.96M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$93.89M | n/m | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | -$128.68M | n/m | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | -$145.66M | n/m | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | -$117.21M | n/m | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | -$108.53M | n/m | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | -$78.50M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$46.39M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$30.09M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$26.48M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$21.39M | n/m | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | -$7.46M | n/a | 2018-03-07, From 2015-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$93.89M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | -$24.99M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$190.82M | n/m |
| Insmed Inc (INSM) | 2025-12-31 | -$967.58M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$472.00M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $136.42M | +436.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $45.99M | -73.1% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $121.23M | -29.7% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | -$24.46M | n/m |
Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗